ASCO® Genitourinary Cancers Symposium 2022


Enfortumab Vedotin | Urothelial Carcinoma | Abstract #TPS589

Study EV-302: A 2-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (Trial in Progress)

Enfortumab Vedotin | Bladder Cancer | Abstract #TPS587

Study EV-103 Cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (Trial in Progress)

Enfortumab Vedotin | Solid Tumors | Abstract #568

Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

Urothelial Carcinoma | Abstract #570

Systematic literature review (SLR) and network meta-analysis (NMA) of first-linetherapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC)

Tucatinib | Urothelial Cancer | Abstract #TPS586

SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress)

Enfortumab Vedotin | Bladder Cancer | Abstract #435

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible